Management of immune checkpoint inhibitor‐related rheumatic adverse events

Immune checkpoint inhibitors (ICIs), which target the programmed cell death receptor‐1 and cytotoxic T lymphocyte‐associated antigen‐4 signaling pathways, represent remarkable breakthroughs in cancer treatment and have improved survival among patients with a variety of malignancies. However, the wid...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Thorac Cancer
Main Authors: Zhou, Jiaxin, Wang, Hanping, Guo, Xiaoxiao, Wang, Qian, Duan, Lian, Si, Xiaoyan, Zhang, Li, Liu, Xiaowei, Li, Yue, Zhang, Wen
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons Australia, Ltd 2019
Teme:
Clinical Guidelines
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6938753/
https://ncbi.nlm.nih.gov/pubmed/31762209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13249
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki